FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979497515> ?p ?o ?g. }

• W2979497515 endingPage "2179" @default.
• W2979497515 startingPage "2179" @default.
• W2979497515 abstract "Abstract Background: The clinical efficacy of hydroxyurea (HU) in patients with sickle cell anemia (SCA) is well established. In clinical trials, HU has been demonstrated to alter the clinical course of SCA; HU decreases rates of pain, dactylitis, acute chest syndrome (ACS), transfusions, hospitalizations and improves hemoglobin levels. Other studies have shown that HU improves quality of life and decreases mortality. While evidence of efficacy has been well demonstrated, published data about clinical effectiveness is limited. Additionally, attempts to compare outcomes of patients taking HU to those not taking HU have been limited by the inherent selection bias for greater disease severity in patients on HU. We sought to examine the clinical effectiveness of HU in the large population of patients with sickle cell disease (SCD) at Children's Healthcare of Atlanta (CHOA). The program provides comprehensive care to >1,700 active patients; because they include about 95% of all children and adolescents with SCD in the greater Atlanta Metropolitan Area, the program provides a population-based sample. Currently 57% of the 922 children ≥ 1 yr of age with SCA (SS and Sβ0 thalassemia) who are not on chronic transfusions are receiving HU. Methods: Using a retrospective cohort, pre-post treatment study design to control for disease severity selection bias we evaluated the clinical effectiveness of HU in patients with SCA who received care at CHOA and who first initiated HU in 2009-2011. Children on chronic transfusions, or children with inadequate follow up data and/or who ever took HU in the 3 years prior were excluded. Clinical guidelines for dosing HU have been standardized locally and recommend initial dosage of 20mg/kg/day, followed by dose escalation every 2 months to maximum tolerated dose. For each patient, healthcare utilization, laboratory values and clinical outcomes for the 2-year period prior to HU initiation were compared to those for two years after initiation. Medians were compared using the Wilcoxon Signed Rank test and means using T test. Rate ratios were computed using unadjusted Poisson regression. Interactions testing whether the effect of HU varied by age, sex, or insurance status, were assessed using multivariable Poisson regression. Results: Of 211 children with SCA who initiated HU in 2009-2011, 134 met eligibility criteria. After initiation of HU, the rate of hospitalization was 0.53 the rate before HU, a 47% reduction (Table). The number of inpatient days, emergency room (ER) visits, pain encounters, episodes of acute chest syndrome (ACS), and transfusions were also significantly reduced (Table). The hemoglobin level (mean +/- SD) pre- and post-HU initiation was 7.3+/-2.7 g /dl and 8.1+/- 2.9 respectively; an increase of 0.8+/-1.1, p<0.0001. Similarly, pre-HU mean corpuscular volume increased from 82.9+/-7.5 fl pre-HU to 95.7+/-10.7 post-HU; an increase of 12.8+/-7.2, p <0.0001. There was a statistically significant interaction between the effect of HU and age of initiation of the drug on hospitalization rates; patients < 7 years of age had a greater reduction in hospitalizations than older children (58% vs 33%, p=0.03). The effect of HU on hospitalizations did not vary by sex or insurance type. Table 1. Effect of HU initiation on clinical outcomes using Poisson Regression Rate Ratio (Confidence Limits) P Value Hospitalizations 0.53 (0.43 - 0.66) <0.0001 Inpatient Days 0.50 (0.40 - 0.63) <0.0001 ER visits 0.57 (0.49 - 0.67) <0.0001 Pain Encounters 0.64 (0.51 - 0.81) 0.0001 ACS 0.57 (0.39 - 0.83) 0.0036 Blood Exposure 0.43 (0.29 - 0.64) <0.0001 Conclusions: HU is clinically effective in children and adolescents with SCA. HU decreased hospitalizations, ER visits, pain encounters, ACS, use of transfusions and improved hemoglobin levels. HU effectiveness was similar across gender, insurance types and age, although there was a slightly greater reduction in hospitalizations in younger patients. These results are important as they parallel results obtained from HU efficacy studies, thus demonstrating that in 'real life' settings, even without the additional monitoring and adherence incentives of clinical trials, HU improves short-term outcomes in pediatric SCA. Disclosures Off Label Use: Hydroxyurea use as disease modifying therapy in pediatric patients with sickle cell disease." @default.
• W2979497515 created "2019-10-18" @default.
• W2979497515 creator A5003492597 @default.
• W2979497515 creator A5014275291 @default.
• W2979497515 creator A5016317121 @default.
• W2979497515 creator A5025324943 @default.
• W2979497515 creator A5036026811 @default.
• W2979497515 creator A5049234597 @default.
• W2979497515 creator A5051820244 @default.
• W2979497515 creator A5058186337 @default.
• W2979497515 creator A5063557553 @default.
• W2979497515 creator A5069277194 @default.
• W2979497515 date "2015-12-03" @default.
• W2979497515 modified "2023-09-26" @default.
• W2979497515 title "Hydroxyurea Effectiveness in Children and Adolescents with Sickle Cell Anemia: A Large Retrospective, Population-Based Cohort Study" @default.
• W2979497515 doi "https://doi.org/10.1182/blood.v126.23.2179.2179" @default.
• W2979497515 hasPublicationYear "2015" @default.
• W2979497515 type Work @default.
• W2979497515 sameAs 2979497515 @default.
• W2979497515 citedByCount "1" @default.
• W2979497515 countsByYear W29794975152018 @default.
• W2979497515 crossrefType "journal-article" @default.
• W2979497515 hasAuthorship W2979497515A5003492597 @default.
• W2979497515 hasAuthorship W2979497515A5014275291 @default.
• W2979497515 hasAuthorship W2979497515A5016317121 @default.
• W2979497515 hasAuthorship W2979497515A5025324943 @default.
• W2979497515 hasAuthorship W2979497515A5036026811 @default.
• W2979497515 hasAuthorship W2979497515A5049234597 @default.
• W2979497515 hasAuthorship W2979497515A5051820244 @default.
• W2979497515 hasAuthorship W2979497515A5058186337 @default.
• W2979497515 hasAuthorship W2979497515A5063557553 @default.
• W2979497515 hasAuthorship W2979497515A5069277194 @default.
• W2979497515 hasBestOaLocation W29794975151 @default.
• W2979497515 hasConcept C126322002 @default.
• W2979497515 hasConcept C167135981 @default.
• W2979497515 hasConcept C187212893 @default.
• W2979497515 hasConcept C2776260265 @default.
• W2979497515 hasConcept C2777799968 @default.
• W2979497515 hasConcept C2778019847 @default.
• W2979497515 hasConcept C2778248108 @default.
• W2979497515 hasConcept C2778620579 @default.
• W2979497515 hasConcept C2779134260 @default.
• W2979497515 hasConcept C2780131103 @default.
• W2979497515 hasConcept C2780976302 @default.
• W2979497515 hasConcept C2908647359 @default.
• W2979497515 hasConcept C535046627 @default.
• W2979497515 hasConcept C71924100 @default.
• W2979497515 hasConcept C72563966 @default.
• W2979497515 hasConcept C99454951 @default.
• W2979497515 hasConceptScore W2979497515C126322002 @default.
• W2979497515 hasConceptScore W2979497515C167135981 @default.
• W2979497515 hasConceptScore W2979497515C187212893 @default.
• W2979497515 hasConceptScore W2979497515C2776260265 @default.
• W2979497515 hasConceptScore W2979497515C2777799968 @default.
• W2979497515 hasConceptScore W2979497515C2778019847 @default.
• W2979497515 hasConceptScore W2979497515C2778248108 @default.
• W2979497515 hasConceptScore W2979497515C2778620579 @default.
• W2979497515 hasConceptScore W2979497515C2779134260 @default.
• W2979497515 hasConceptScore W2979497515C2780131103 @default.
• W2979497515 hasConceptScore W2979497515C2780976302 @default.
• W2979497515 hasConceptScore W2979497515C2908647359 @default.
• W2979497515 hasConceptScore W2979497515C535046627 @default.
• W2979497515 hasConceptScore W2979497515C71924100 @default.
• W2979497515 hasConceptScore W2979497515C72563966 @default.
• W2979497515 hasConceptScore W2979497515C99454951 @default.
• W2979497515 hasIssue "23" @default.
• W2979497515 hasLocation W29794975151 @default.
• W2979497515 hasOpenAccess W2979497515 @default.
• W2979497515 hasPrimaryLocation W29794975151 @default.
• W2979497515 hasRelatedWork W2050718333 @default.
• W2979497515 hasRelatedWork W2141187979 @default.
• W2979497515 hasRelatedWork W2188367746 @default.
• W2979497515 hasRelatedWork W242090125 @default.
• W2979497515 hasRelatedWork W2581790269 @default.
• W2979497515 hasRelatedWork W4232862935 @default.
• W2979497515 hasRelatedWork W4234382646 @default.
• W2979497515 hasRelatedWork W4240068935 @default.
• W2979497515 hasRelatedWork W2182395909 @default.
• W2979497515 hasRelatedWork W3088975555 @default.
• W2979497515 hasVolume "126" @default.
• W2979497515 isParatext "false" @default.
• W2979497515 isRetracted "false" @default.
• W2979497515 magId "2979497515" @default.
• W2979497515 workType "article" @default.